CONTACT

Leiter Prof. Christian Müller Spitalstrasse 2 CH-4056 Basel Schweiz

Study News

Horizon Horizon is a randomized, Phase 3, placebo-controlled, multicenter, double-blind study (sponsor Novartis) evaluating the impact of lipoprotein (a) on major cardiovascular events in patients with established cardiovascular disease (CVD). The study consists of a screening period of approximately 2 weeks, followed by a period of CV risk factor therapy optimization of approximately 4 -12 weeks, if needed, and a double-blind treatment period. Eligible patients will be randomized after screening or after the 'CV risk factor therapy optimization' period to receive subcutaneous injections of TQJ230 80 mg QM or placebo for self-administration or administration by a nurse or site staff approximately every 30 days. The minimum follow-up time in the double-blind trial is 2.5 years, and the total duration of the study is expected to be approximately 4.25 years. In Switzerland, 60 patients are planned to be enrolled. Study Coordinator: Dr. Ina-Ferel

dyspnea.ch

FORSCHUNG HERZCHIRURGIE